Noninfectious Neurologic Complications after Allogeneic Hematopoietic Stem Cell Transplantation

Autor: Ignacio Lorenzo, Pilar Solves, Aitana Balaguer-Roselló, Nuria Muelas, José Luis Piñana, Teresa Sevilla, Guillermo Sanz, Manuel Guerreiro, Carlos Carretero, Miguel A. Sanz, Marta Santiago, Carmen Freiria, Jaime Sanz, Ana Villalba, Juan Montoro, Luis Bataller, Inés Gómez
Rok vydání: 2019
Předmět:
Zdroj: BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
ISSN: 1083-8791
DOI: 10.1016/j.bbmt.2019.05.024
Popis: Although allogeneic hematopoietic stem cell transplantation (allo-HSCT) can be associated with neurologic complications, data on noninfectious etiologies are scanty. Therefore, we analyzed the incidence, clinical characteristics, risk factors, and influence on outcomes of noninfectious neurologic complications (NCs) in 971 consecutive patients with hematologic malignancies undergoing allo-HSCT at our center between January 2000 and December 2016. We evaluated NCs affecting the central nervous system (CNS) and peripheral nervous system (PNS). The median duration of follow-up of survivors was 71 months (range, 11 to 213 months). A total of 467 patients received a matched sibling donor (MSD) transplant, 381 received umbilical cord blood (UCB), 74 received a haploidentical transplant, and 49 received a matched unrelated donor (MUD) transplant. One hundred forty-nine (15.3%) NCs were documented at a median of 78 days after transplantation (range, 5 days before to 3722 days after). The cumulative incidence risk of developing NC was 7.5% (95% confidence interval, 6% to 8.2%) at day +90 and 13% at 5 years. The 5 -year cumulative incidence of NCs was 10.8% after MSD alto-HSCT and 15.3% after alternative donor (UCB, MUD, haploidentical) allo-HSCT (P=.004). There were 101 (68%) CNS complications, including encephalopathy, n = 46 (31%); headache, n = 20 (13%); stroke, n = 15 (10%); seizures, n = 9 (6%), posterior reversible encephalopathy syndrome, n = 6 (4%), and myelopathy, n = 5 (3%). PNS complications (32%) included neuropathies, n = 25 (17%), and myopathies and neuromuscular junction disorders, n = 23 (17%), with 17% of the total PNS complications being immune-related. In multivariable analysis, donor type other than MSD, age >= 40 years, development of acute graft-versus-host disease (GVHD) grade II-IV (hazard ratio [HR], 3.3; P < .00001), and extensive chronic GVHD (HR, 3.2; P=.0002) were independently associated with increased risk of NCs. The 5 -year overall survival (OS) was 21% in patients who developed NCs and 41% for those who did not (P < .0001). This difference in OS was observed in patients developing CNS NCs, but not in those developing PNS complications. In conclusion, our study reveals NCs as a frequent and heterogeneous complication that, when affecting CNS, is associated with poor prognosis following allo-HSCT. (C) 2019 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.
Databáze: OpenAIRE
Externí odkaz: